Llwytho...
Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib
BACKGROUND: This work set out to examine the hematological adverse events (AEs) of an individualized starting dose (ISD) of niraparib in Chinese patients with ovarian cancer (OC). METHODS: The medical records of 43 patients with OC who were treated with an ISD of niraparib at the Cancer Hospital of...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ann Transl Med |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
AME Publishing Company
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8184470/ https://ncbi.nlm.nih.gov/pubmed/34164503 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-21-2252 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|